Balancing Benefit and Toxicity from Immunotherapeutics

Jeffrey Weber, Deputy Director at Laura and Isaac Perlmutter Cancer Center and Co-director of Melanoma Program and Head of Experimental Therapeutics at NYU Langone Medical Center, discusses the day to day management of, and the science around, IO adverse events that may help us understand how these drugs work. Including:

• The need to educate physicians about management of immune related adverse events with increasing penetration of checkpoint inhibitors into the community
• The relationship of these adverse events to outcome with checkpoint inhibition
• The relation of adverse events to other autoimmune diseases that are similar in nature

This session was presented at the 4th annual Immuno-Oncology 360 conference in February 2018.

For more information on the IO360 conference and details for the 5th annual program taking place February 6-8, 2019 in New York, NY, please visit io360summit.com.